Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

463
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
147
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plumbagin Triggers STING Pathway Activation to Suppress Non-Small Cell Lung Cancer Progression.

Chemical biology & drug design·2025
Same author

Brazilin Inhibits the Proliferation of Non-Small Cell Lung Cancer by Regulating the STING/TBK1/IRF3 Pathway.

Journal of cellular and molecular medicine·2025
Same author

Evaluation and correction methods for geometric errors of hydrostatic thrust bearings.

Scientific reports·2024
Same author

Predicting immunotherapy-related adverse events in late-stage non-small cell lung cancer with KARS G12C mutation treated with PD-1 inhibitors through combined assessment of LCP1 and ADPGK expression levels.

American journal of cancer research·2024
Same author

Enhancing genomic association studies in slash pine through close-range UAV-based morphological phenotyping.

Forestry research·2024
Same author

Engineering organoids-on-chips for drug testing and evaluation.

Metabolism: clinical and experimental·2024

Related Experiment Video

Updated: May 26, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

644

Rutecarpine Suppresses Non-Small Cell Lung Cancer Progression Through Activating the STING Pathway and Elevating CD8+

Ze-Bo Jiang1,2, Qing-Hua He3, Li-Ping Kang1,2

  • 1Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai, Guangdong, China.

Chemical Biology & Drug Design
|February 24, 2025
PubMed
Summary

Rutecarpine (RUT) shows promise as an anti-cancer drug for non-small cell lung cancer (NSCLC). It induces apoptosis and inhibits tumor growth by activating the STING pathway and boosting CD8+ T cells.

Keywords:
CD8+ TCXCL10STINGlung cancerrutecarpine

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.1K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

2.9K

Related Experiment Videos

Last Updated: May 26, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

644
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.1K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

2.9K

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide.
  • Rutecarpine (RUT), a natural alkaloid, exhibits anticancer potential but its mechanisms in NSCLC are not fully understood.

Purpose of the Study:

  • To elucidate the antitumor mechanisms of Rutecarpine (RUT) in non-small cell lung cancer (NSCLC).
  • To evaluate the therapeutic potential of RUT as an anti-cancer drug for NSCLC.

Main Methods:

  • Investigated RUT's effects on NSCLC cell viability, apoptosis, and reactive oxygen species (ROS) production.
  • Analyzed RUT's impact on CXCL10, CCL5, STING pathway activation, and PD-L1 levels in NSCLC cells.
  • Assessed RUT's efficacy in inhibiting tumor growth and modulating immune response in a mouse model of NSCLC.

Main Results:

  • RUT significantly reduced NSCLC cell viability and induced apoptosis via ROS stimulation and mitochondrial dysfunction.
  • RUT therapy increased CXCL10 and CCL5 production, activated the STING pathway, and decreased PD-L1 levels in NSCLC cells.
  • In vivo, RUT inhibited tumor growth and enhanced CD8+ T cell infiltration in mouse NSCLC models.

Conclusions:

  • Rutecarpine demonstrates significant anti-NSCLC activity through ROS modulation, immune pathway activation, and PD-L1 downregulation.
  • RUT exhibits promising therapeutic potential as an anti-cancer agent for non-small cell lung cancer.